Eli Lilly is positioned to potentially beat earnings estimates again when it reports on October 29, 2026, according to Zacks Investment Research. The drugmaker has topped estimates by 30.27% on average over the last two quarters, reporting $8.38 per share against a $6.01 consensus in the most recent quarter, a surprise of 39.43%, and $8.55 per share against a $7.06 consensus in the prior quarter, a surprise of 21.10%. Lilly currently carries a Zacks Earnings ESP of +0.64% alongside a Zacks Rank #3 (Hold), a combination that Zacks research shows produces a positive surprise nearly 70% of the time. The Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, capturing analyst revisions made just before an earnings release.
Eli Lilly and CompanyZacks Earnings ESP of +0.64% and strong recent beats point to another earnings beat on October 29, 2026.
